New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections

Lynn Dover, Apoorva Bhatt, Veemal Bhowruth, Benjamin Willcox, Gurdyal Besra

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
37 Downloads (Pure)


Tuberculosis remains the most common cause of death due to a single infective organism. Despite the availability of a vaccine and chemotherapeutic options, the global disease burden remains relatively unaffected. The ability of the mycobacterial etiological agents to adopt a semidormant, phenotypically drug-resistant state requires that chemotherapy is both complex and lengthy. The emergence of drug resistance has raised the possibility of virtually untreatable tuberculosis. Furthermore, the currently used bacillus Calmette–Guerin vaccine has had mixed success in protecting susceptible populations. Given this backdrop, the need for novel anti-infectives and more effective vaccines is clearly evident. Recent progress, described herein, has seen the development and entry into clinical trials of several new drugs and vaccine candidates
Original languageEnglish
Pages (from-to)481-497
JournalExpert Review of Vaccines
Issue number4
Publication statusPublished - May 2008


Dive into the research topics of 'New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections'. Together they form a unique fingerprint.

Cite this